Bilaketaren emaitzak - Rodrigues, D N

Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail nork Ong, M, Carreira, S, Goodall, J, Mateo, J, Figueiredo, I, Rodrigues, D N, Perkins, G, Seed, G, Yap, T A, Attard, G, de Bono, J S

Testu osoa Testu osoa Testu osoa

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents nork Crespo, M, van Dalum, G, Ferraldeschi, R, Zafeiriou, Z, Sideris, S, Lorente, D, Bianchini, D, Rodrigues, D N, Riisnaes, R, Miranda, S, Figueiredo, I, Flohr, P, Nowakowska, K, de Bono, J S, Terstappen, L W M M, Attard, G

Testu osoa Testu osoa Testu osoa

CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair nork Shenoy, T. R., Boysen, G., Wang, M. Y., Xu, Q. Z., Guo, W., Koh, F. M., Wang, C., Zhang, L. Z., Wang, Y., Gil, V., Aziz, S., Christova, R., Rodrigues, D. N., Crespo, M., Rescigno, P., Tunariu, N., Riisnaes, R., Zafeiriou, Z., Flohr, P., Yuan, W., Knight, E., Swain, A., Ramalho-Santos, M., Xu, D. Y., de Bono, J., Wu, H.

Testu osoa Testu osoa Testu osoa